Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

JNJ

Johnson & Johnson

Oct 03 • 04:00PM ET

160.50

Dollar change -0.67
Percentage change -0.42	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Held by: VTI VOO SPY IVV VTV XLV VIG VYM QUAL VHT

Scroll to Statements

Index	DJIA, S&P 500	P/E	23.20	EPS (ttm)	6.92	Insider Own	0.12%	Shs Outstand	2.41B	Perf Week	-0.55%
Market Cap	386.36B	Forward P/E	15.01	EPS next Y	10.69	Insider Trans	-0.19%	Shs Float	2.40B	Perf Month	-4.10%
Income	17.03B	PEG	4.19	EPS next Q	2.19	Inst Own	72.38%	Short Float	0.96%	Perf Quarter	9.57%
Sales	86.57B	P/S	4.46	EPS this Y	0.66%	Inst Trans	-0.39%	Short Ratio	3.50	Perf Half Y	5.25%
Book/sh	29.72	P/B	5.40	EPS next Y	7.06%	ROA	8.79%	Short Interest	23.03M	Perf Year	3.32%
Cash/sh	10.58	P/C	15.17	EPS next 5Y	5.53%	ROE	22.34%	52W Range	143.13 - 168.85	Perf YTD	2.40%
Dividend Est.	4.65 (2.90%)	P/FCF	19.03	EPS past 5Y	-0.27%	ROI	16.51%	52W High	-4.95%	Beta	0.52
Dividend TTM	4.86 (3.03%)	Quick Ratio	0.85	Sales past 5Y	1.31%	Gross Margin	68.75%	52W Low	12.14%	ATR (14)	1.98
Dividend Ex-Date	Aug 27, 2024	Current Ratio	1.07	EPS Y/Y TTM	39.69%	Oper. Margin	25.94%	RSI (14)	40.54	Volatility	1.01% 1.25%
Employees	131900	Debt/Eq	0.58	Sales Y/Y TTM	-11.50%	Profit Margin	19.68%	Recom	2.26	Target Price	171.63
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	-1.24%	Payout	84.93%	Rel Volume	0.71	Prev Close	161.17
Sales Surprise	0.52%	EPS Surprise	4.01%	Sales Q/Q	-12.12%	Earnings	Oct 15 BMO	Avg Volume	6.58M	Price	160.50
SMA20	-2.20%	SMA50	-1.17%	SMA200	3.03%	Trades		Volume	4,697,821	Change	-0.42%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-23-24	Downgrade	Daiwa Securities	Outperform → Neutral	$160 → $150
May-30-24	Resumed	Goldman	Neutral	$160
Apr-18-24	Upgrade	HSBC Securities	Hold → Buy	$170
Dec-13-23	Downgrade	Wells Fargo	Overweight → Equal Weight	$170 → $163
Dec-01-23	Upgrade	UBS	Neutral → Buy	$167 → $180
Oct-05-23	Initiated	RBC Capital Mkts	Outperform	$178
Sep-06-23	Initiated	HSBC Securities	Hold	$175
May-30-23	Resumed	Citigroup	Buy	$185
Mar-29-23	Initiated	UBS	Neutral	$164
Mar-01-23	Initiated	Guggenheim	Neutral	$161
Nov-18-22	Initiated	Credit Suisse	Neutral	$170
Oct-18-22	Initiated	Barclays	Equal Weight	$175
Oct-14-22	Reiterated	BofA Securities	Neutral	$185 → $178
Jun-22-22	Initiated	Daiwa Securities	Outperform
May-23-22	Resumed	SVB Leerink	Outperform	$200
Apr-06-22	Resumed	Morgan Stanley	Equal-Weight	$173
Mar-16-22	Downgrade	Bernstein	Outperform → Mkt Perform	$180 → $183
Mar-02-22	Resumed	BofA Securities	Neutral	$185
Dec-17-21	Initiated	Goldman	Neutral	$161
Dec-15-21	Reiterated	Citigroup	Buy	$192 → $195

Show Previous Ratings

Today 08:30AM	Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More (PR Newswire)
Oct-02-24 11:00AM	Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug (Benzinga)
09:00AM	ERLEADA (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (PR Newswire)
Oct-01-24 03:00PM	55-Year-Old Who Reached $3,900 Per Month Income In Just 5 Years Shares Portfolio: Top 9 Stocks And ETFs (Benzinga)
02:08PM	J&J to invest over $2 billion for new manufacturing facility in North Carolina (Reuters)
08:00AM	Loading…
08:00AM	Unlocking Intrinsic Value: Analysis of Johnson & Johnson (GuruFocus.com)
04:52AM	Johnson & Johnson launches TECNIS Odyssey intraocular lens in US (Medical Device Network)
04:42AM	J&J drops 340B rebate plan following government pressure (Healthcare Dive)
Sep-30-24 04:35PM	J&J Backtracks on Plan Aimed at Hospital Drug-Discount Program (The Wall Street Journal)
04:11PM	Legend Biotech Reverses After J&J-Tied Cancer Drug Cuts Risk Of Death By 45% (Investor's Business Daily)
04:05PM	Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned (PR Newswire)
12:33PM	J&J clinches EC approval for first single-pill PAH combo (Pharmaceutical Technology)
12:23PM	80 Hedge Funds Hold Stakes in Johnson & Johnson (JNJ) as of Q2 2024 (Insider Monkey)
09:46AM	Legend Biotech Rises After J&J-Tied Cancer Drug Cuts Risk Of Death By 45% (Investor's Business Daily)
08:05AM	Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting (PR Newswire)
06:32AM	Loading…
06:32AM	Johnson & Johnsons CARVYKTI improves survival in multiple myeloma trial (Clinical Trials Arena)
06:15AM	15 Best Dividend Stocks for Lifelong Passive Income (Motley Fool)
04:50AM	Johnson & Johnson (JNJ): Hedge Funds Bet Big on Healthcare Giant Amid 4.3% Q2 Revenue Increase (Insider Monkey)
Sep-28-24 08:10AM	Johnson & Johnson announces updated results from Phase 1b RedirecTT-1 study (TipRanks)
08:05AM	Johnson & Johnson provides updated results from Phase 1b TRIMM-2 study (TipRanks)
05:00AM	2 Excellent Dividend Stocks to Buy With Less Than $200 (Motley Fool)
Sep-27-24 04:30PM	Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma (Investor's Business Daily)
04:30PM	CARVYKTI is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line (PR Newswire)
01:05PM	DARZALEX (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma (PR Newswire)
01:00PM	DARZALEX FASPRO-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned (PR Newswire)
12:14PM	Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment (Benzinga)
11:27AM	Analyst Report: Johnson & Johnson (Morningstar Research)
09:00AM	Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know (Zacks)
08:05AM	Novel combination of TALVEY (talquetamab-tgvs) and TECVAYLI (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease (PR Newswire)
08:00AM	TALVEY (talquetamab-tgvs) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma (PR Newswire)
11:50AM	Loading…
Sep-26-24 11:50AM	Is Johnson & Johnson (JNJ) the Best Stock To Buy Right Now According To Billionaire Cliff Asness? (Insider Monkey)
10:21AM	Johnson & Johnson (JNJ): Leveraging Innovation for Sustained Market Leadership (Insider Monkey)
03:54AM	Johnson & Johnson (JNJ): A Good Undervalued Blue Chip Stock to Buy According to Analysts (Insider Monkey)
02:45AM	Johnson & Johnson (JNJ): A Good Holding Company Stock to Buy Now (Insider Monkey)
Sep-25-24 08:32AM	Johnson & Johnson (JNJ): Hedge Funds Are Bullish On This Trending AI Stock Right Now (Insider Monkey)
06:35AM	2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off (Motley Fool)
Sep-24-24 05:45PM	Johnson & Johnson (JNJ) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
Sep-23-24 07:15PM	J&Js Bankruptcy Effort Fails High Court Test, Holdouts Say (Bloomberg)
12:06PM	J&J Needs to End Talc Lawsuits. The Third Time Could Be the Charm. (Barrons.com)
Sep-21-24 11:15AM	Is Johnson & Johnson Stock a Buy? (Motley Fool)
06:41AM	Is Johnson & Johnson (JNJ) the Best Future Stock For The Long-Term? (Insider Monkey)
Sep-20-24 09:15PM	Johnson & Johnson Files Third Bankruptcy Case Seeking to End Talc Lawsuits (The Wall Street Journal)
06:53PM	Attorneys Vow to Oppose J&J's Third Bankruptcy Attempt (Business Wire)
05:44PM	J&J Unit Seeks Chapter 11 Bankruptcy for Third Time Over Baby Powder Suits (Bloomberg)
04:45PM	J&J subsidiary files for bankruptcy to advance $8 billion talc settlement (CNN Business)
03:43PM	Johnson & Johnson Announces that its Subsidiary, Red River Talc LLC, has Filed a Voluntary Prepackaged Chapter 11 Case to Resolve All Current and Future Ovarian Cancer Talc Claims (Business Wire)
03:39PM	J&J unit files for bankruptcy to advance $10 billion talc settlement (Reuters)
01:29PM	Johnson & Johnson's Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients (Benzinga)
01:27PM	Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease (Benzinga)
Sep-19-24 06:54PM	RYBREVANT (amivantamab-vmjw) plus standard of care approved in the U.S. as first and only targeted regimen to cut risk of disease progression by more than half in second-line EGFR-mutated advanced lung cancer (PR Newswire)
Sep-18-24 05:19AM	J&J threatened with sanctions over plan to rebate 340B drugs (Healthcare Dive)
02:29AM	Johnson & Johnson (JNJ) Faces Legal Challenges While Advancing MedTech Innovations for Growth (Insider Monkey)
Sep-17-24 04:55PM	U.S. To J&J: Don't Target Hospital Drug Discounts (The Wall Street Journal)
Sep-16-24 05:45PM	Johnson & Johnson (JNJ) Exceeds Market Returns: Some Facts to Consider (Zacks)
01:26PM	J&J gets $260 million talc verdict overturned in Oregon, new trial ordered (Reuters)
10:55AM	J&Js Shockwave strengths IVL grasp with new US catheter launch (Medical Device Network)
09:00AM	Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:04AM	ESMO24: A cancer cachexia drug, VEGF enthusiasm and immunotherapys survival impact (BioPharma Dive)
08:00AM	Navigating Market Uncertainty: Intrinsic Value of Johnson & Johnson (GuruFocus.com)
06:53AM	Johnson & Johnsons RYBREVANT trial shows improved response rate (Clinical Trials Arena)
02:50AM	Neoadjuvant TAR-200 plus cetrelimab nearly doubles the pathological complete response rate compared to cetrelimab alone in patients with muscle-invasive bladder cancer (PR Newswire)
Sep-15-24 02:30AM	New data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer (PR Newswire)
Sep-14-24 12:39PM	Is Johnson & Johnson (JNJ) the Best Blue Chip Stock To Invest In According to Short Sellers? (Insider Monkey)
09:45AM	RYBREVANT (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer (PR Newswire)
03:10AM	RYBREVANT (amivantamab-vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR-mutated lung cancer (PR Newswire)
Sep-13-24 09:00AM	How Much Would It Take To Earn $1,000 A Month In Dividends With Just Four Stocks? (Benzinga)
07:53AM	Cidara buys back rights to flu therapy from J&J for $85m (Pharmaceutical Technology)
Sep-12-24 08:33AM	How To Earn $500 A Month From Johnson & Johnson Stock (Benzinga)
03:52AM	FDA approves Johnson & Johnsons TREMFYA for ulcerative colitis (Pharmaceutical Technology)
12:17AM	Is Johnson & Johnson (JNJ) the Best Defensive Stock According to Reddit? (Insider Monkey)
Sep-11-24 10:18PM	10 Best Stocks For Beginners With Little Money (Insider Monkey)
06:22PM	TREMFYA (guselkumab) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson's leadership in inflammatory bowel disease (PR Newswire)
07:37AM	J&J leads $50M financing for imaging company Spectrawave (MedTech Dive)
06:59AM	2 Stocks That Are Passive Income Machines to Buy and Hold Forever (Motley Fool)
04:52AM	Johnson & Johnson reports data from Phase II NSCLC treatment trial (Clinical Trials Arena)
Sep-10-24 05:15PM	Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT (amivantamab-vmjw) (PR Newswire)
01:17PM	Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines (Benzinga)
Sep-09-24 05:45PM	Johnson & Johnson (JNJ) Outpaces Stock Market Gains: What You Should Know (Zacks)
06:32AM	J&Js Rybrevant combo for NSCLC remains better than SOC after three years (Clinical Trials Arena)
06:03AM	Three Things To Know To Build A Dividend Portfolio For Passive Income (Benzinga)
Sep-08-24 04:12PM	Johnson & Johnson (JNJ): A Magic Formula Stock You Should Pay Attention To (Insider Monkey)
01:47PM	RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) show strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer (PR Newswire)
11:53AM	10 Best Magic Formula Stocks For The Rest Of 2024 (Insider Monkey)
Sep-06-24 08:19AM	Judge orders J&J to pay Auris investors more than $1B for merger violations (MedTech Dive)
Sep-05-24 04:30PM	Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results (Business Wire)
09:00AM	Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know (Zacks)
07:55AM	2 Dividend Stocks With Payouts That May Not Be as Safe as They Seem (Motley Fool)
Sep-04-24 07:20PM	Johnson & Johnson Wins Over Longtime Holdout for Talc Settlement (The Wall Street Journal)
04:12PM	Johnson & Johnson adds $1.1 billion to proposed talc settlement (Reuters)
11:00AM	Judge rules J&J owes Auris investors $1 billion related to 2019 robotics deal (Reuters)
08:26AM	3 Dividend Stocks to Double Up on Right Now (Motley Fool)
Sep-03-24 11:32PM	Is Johnson & Johnson (JNJ) the Best Cancer Stock to Buy Now? (Insider Monkey)
05:45PM	Johnson & Johnson (JNJ) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Sep-02-24 09:05PM	Johnson & Johnson (JNJ): Among ChatGPTs Recent Stock Recommendations (Insider Monkey)
05:07PM	Johnson & Johnson (JNJ): A Good 52-Week High Stock to Buy According to Short Sellers (Insider Monkey)
08:01AM	Unlocking Intrinsic Value: Analysis of Johnson & Johnson (GuruFocus.com)
06:53AM	Johnson & Johnson picks Onco360 as pharmacy partner for LAZCLUZE (Pharmaceutical Technology)
Sep-01-24 12:00PM	These Four Dividend Kings Could Thrive Even If The Consumer Falters (Benzinga)
06:45AM	Is Johnson & Johnson the Best Dividend Stock for You? (Motley Fool)
05:12AM	Worried About a Stock Market Sell-Off? Consider Coca-Cola, Pepsi, and These 3 Safe Dividend Kings for Decades of Passive Income. (Motley Fool)

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Decker Robert J	VP Corporate Controller	Aug 30 '24	Option Exercise	100.06	5,635	563,838	24,608	Sep 03 04:48 PM
Decker Robert J	VP Corporate Controller	Aug 30 '24	Sale	165.06	5,635	930,113	18,973	Sep 03 04:48 PM
Decker Robert J	Officer	Aug 30 '24	Proposed Sale	165.06	5,635	930,113		Aug 30 03:51 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Jul 08 '24	Option Exercise	0.00	9,809	0	24,852	Jul 09 05:48 PM
REED JOHN C	EVP, Innovative Medicine, R&D	May 01 '24	Option Exercise	0.00	22,255	0	22,561	May 03 04:31 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Mar 13 '24	Sale	162.16	8,891	1,441,765	15,043	Mar 13 04:36 PM
JOHNSON & JOHNSON	10% Owner	Feb 29 '24	Option Exercise	0.72	3,855	2,792	4,103,430	Mar 06 03:42 PM
JOHNSON & JOHNSON	10% Owner	Feb 16 '24	Sale	25.81	3,725	96,142	4,099,575	Mar 06 03:42 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 13 '24	Option Exercise	0.00	651	0	82,599	Feb 15 04:53 PM
Wolk Joseph J	Exec VP, CFO	Feb 13 '24	Option Exercise	0.00	1,780	0	69,663	Feb 15 04:53 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 13 '24	Option Exercise	0.00	1,302	0	155,517	Feb 15 04:53 PM
Swanson James D.	EVP, CIO	Feb 13 '24	Option Exercise	0.00	447	0	14,765	Feb 15 04:53 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 13 '24	Option Exercise	0.00	499	0	13,290	Feb 15 04:53 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 13 '24	Option Exercise	0.00	925	0	112,550	Feb 15 04:53 PM
Hait William	See Remarks	Feb 13 '24	Option Exercise	0.00	834	0	39,074	Feb 15 04:53 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 13 '24	Option Exercise	0.00	3,470	0	364,809	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 13 '24	Option Exercise	0.00	408	0	24,143	Feb 15 04:53 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 13 '24	Option Exercise	0.00	651	0	8,576	Feb 15 04:53 PM
Decker Robert J	VP Corporate Controller	Feb 13 '24	Option Exercise	0.00	313	0	19,059	Feb 15 04:53 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 12 '24	Option Exercise	0.00	4,701	0	25,081	Feb 14 06:36 PM
Hait William	See Remarks	Feb 12 '24	Option Exercise	0.00	8,932	0	42,316	Feb 14 06:36 PM
Wolk Joseph J	Exec VP, CFO	Feb 12 '24	Option Exercise	0.00	25,835	0	78,699	Feb 14 06:36 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 12 '24	Option Exercise	0.00	2,859	0	8,959	Feb 14 06:36 PM
Taubert Jennifer L	EVP, WWC. Innovative Medicine	Feb 12 '24	Option Exercise	0.00	26,202	0	167,618	Feb 14 06:36 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 12 '24	Option Exercise	0.00	14,960	0	118,644	Feb 14 06:36 PM
Swanson James D.	EVP, CIO	Feb 12 '24	Option Exercise	0.00	5,456	0	16,013	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 12 '24	Option Exercise	0.00	36,618	0	377,239	Feb 14 06:36 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 12 '24	Option Exercise	0.00	5,736	0	15,678	Feb 14 06:36 PM
Decker Robert J	VP Corporate Controller	Feb 12 '24	Option Exercise	0.00	1,912	0	19,269	Feb 14 06:36 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 12 '24	Option Exercise	0.00	13,813	0	89,014	Feb 14 06:36 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 09 '24	Option Exercise	90.44	130,969	11,844,836	439,283	Feb 13 05:18 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Option Exercise	90.44	59,397	5,371,865	200,813	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 08 '24	Option Exercise	0.00	3,739	0	143,329	Feb 12 07:25 PM
Taubert Jennifer L	EVP, WW Chair, Pharmaceuticals	Feb 09 '24	Sale	156.27	59,397	9,281,969	141,416	Feb 12 07:25 PM
Duato Joaquin	CEO and Chairman of the Board	Feb 08 '24	Option Exercise	0.00	5,225	0	310,583	Feb 12 07:25 PM
Wengel Kathryn E	EVP, Chief TO and Risk Officer	Feb 08 '24	Option Exercise	0.00	1,971	0	67,905	Feb 12 07:25 PM
Wolk Joseph J	Exec VP, CFO	Feb 08 '24	Option Exercise	0.00	3,686	0	53,911	Feb 12 07:25 PM
Forminard Elizabeth	Executive VP, General Counsel	Feb 08 '24	Option Exercise	0.00	979	0	6,463	Feb 12 07:24 PM
Swanson James D.	See Remarks	Feb 08 '24	Option Exercise	0.00	1,868	0	11,111	Feb 12 07:24 PM
Schmid Timothy	EVP, WW Chair, MedTech	Feb 08 '24	Option Exercise	0.00	1,964	0	10,943	Feb 12 07:24 PM
Fasolo Peter	Exec VP, Chief HR Officer	Feb 08 '24	Option Exercise	0.00	2,135	0	104,465	Feb 12 07:24 PM
Hait William	See Remarks	Feb 08 '24	Option Exercise	0.00	3,059	0	34,497	Feb 12 07:24 PM
Broadhurst Vanessa	EVP, Global Corp Affairs	Feb 08 '24	Option Exercise	0.00	1,880	0	21,083	Feb 12 07:24 PM
Decker Robert J	VP Corporate Controller	Feb 08 '24	Option Exercise	0.00	655	0	17,572	Feb 12 07:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JNJ

Johnson & Johnson

Upgrade your FINVIZ experience